SITA (Should I Take Aspirin?) Trial: A Randomised Control Trial of a decision aid to support informed choices about taking aspirin to prevent cancer and other chronic disease.
Project Details
Australian aspirin guidelines recommend that all people aged 50-70 years old actively consider taking daily low-dose aspirin for 2.5 to 5 years to reduce their risk of colorectal cancer (CRC).(1) This trial, SITA, is a randomised controlled trial (RCT) with general practice patients that aims to test the efficacy of a health consultation and use of a sex-specific decision aid, using an expected frequency tree (EFT) to present the benefits and harms of taking low dose aspirin, on two co-primary outcomes including informed decision-making at one month and uptake of aspirin at six-months. Control participants receive general information about modifiable risk factors for CRC prevention.
Researchers
Research Team
Ms. Shakira R Milton, Trial Coordinator
A/Prof Jennifer McIntosh
Dr. Sibel Saya
Prof Finlay Macrae
Dr. Patty Chondros
Ms. Lucy Boyd
Ms. Rushani Wijesuriya
Ms. Napin Karnchanachari
Ms. Kitty Novy
A/Prof Natalie Taylor
Prof Mark Jenkins
Dr. Fiona Walter
Prof Lyndal Trevena
Herman Prof Jon Emery
Dr. Javiera Martinez Gutierrez
Ms. Kate Broun
Ms. Sarah McGill
Dr. Sara Whitburn
Consumers
George Fishman
Julie Marker
Max Shub
Collaborators
The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
Funding
The Victorian Comprehensive Cancer Centre’s (VCCC) Precision Prevention Program and the Victorian Cancer Agency.
Research Outcomes
This trial will provide evidence about the use of a decision aid to support informed choices about using low dose aspirin to reduce risk of cancer.